PT Kalbe Farma TbkFRA:LCLA 77 3-Year ROIIC % is 17.28 as of Dec. 2025, which is 75% above its 10-year median of 9.87. GuruFocus rates FRA:LCLA with a GF Score™ of 77/100 and a GF Value™ of €0.10 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 944 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks better than 68.33% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
PT Kalbe Farma Tbk's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 17.28%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for PT Kalbe Farma Tbk's 3-Year ROIIC % or its related term are showing as below:
FRA:LCLA's 3-Year ROIIC % is ranked better than 68.33% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs FRA:LCLA: 17.28
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
PT Kalbe Farma Tbk 3-Year ROIIC % Related Terms
PT Kalbe Farma Tbk 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for PT Kalbe Farma Tbk's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LCLA vs LLY, JNJ, ABBV: 3-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
PT Kalbe Farma Tbk (FRA:LCLA) has a 3-Year ROIIC % of 17.28 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on PT Kalbe Farma Tbk and its competitors. This is 75% above median its historical median of 9.87. Over the past decade, PT Kalbe Farma Tbk's 3-Year ROIIC % has ranged from 0.12 to 20.56. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #299 out of 944 companies in the Drug Manufacturers industry, placing it in the top 31.7%.
Is PT Kalbe Farma Tbk's 3-Year ROIIC % too high?
PT Kalbe Farma Tbk's current 3-Year ROIIC % of 17.28 is 75% above median its 10-year median of 9.87. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 20.56. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. PT Kalbe Farma Tbk's value of 17.28 is 375.4% above this industry median. Based on the distribution chart, PT Kalbe Farma Tbk ranks #299 out of 944 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's 3-Year ROIIC % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #299 out of 944 companies for 3-Year ROIIC %. This puts PT Kalbe Farma Tbk in the upper half of its industry. The industry median 3-Year ROIIC % is 3.64. PT Kalbe Farma Tbk's value of 17.28 is 375.4% above this benchmark. Historically, PT Kalbe Farma Tbk's own 3-Year ROIIC % has ranged from 0.12 to 20.56 over the past decade. While the company's 10-year median is 9.87 vs. the industry median of 3.64, PT Kalbe Farma Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kalbe Farma Tbk's current 3-Year ROIIC % of 17.28 is 375.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on PT Kalbe Farma Tbk and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kalbe Farma Tbk's current 3-Year ROIIC % is 17.28, which is 75% above median its own 10-year median of 9.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.10, compared to a current price of €0.03 — trading 72% below its estimated fair value. The current 3-Year ROIIC % is 17.28, which is 75% above median its 10-year median of 9.87 and 375.4% above the Drug Manufacturers industry median of 3.64. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current 3-Year ROIIC % is 17.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.03 is trading 72% below its estimated GF Value™ of €0.10.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for FRA:LCLA:
3-Year ROIIC %: 17.28 (75% above median its 10-year median of 9.87)
GF Value™: €0.10 vs. price of €0.03 (72% below fair value)
Industry Position: 375.4% above the Drug Manufacturers median (#299 of 944)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for FRA:LCLA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
